Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer.

International journal of molecular sciences·2026
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer.

The Journal of clinical investigation·2026
Same author

Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Molecular cancer research : MCR·2026
Same author

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

EMBO molecular medicine·2026

Related Experiment Video

Updated: Jan 10, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.8K

Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer.

Yongtao Li1, Zhicheng Zhou1, Yiqun Zhang2

  • 1Department of Urology, University of Washington, Seattle, WA, USA.

Oncogene
|November 25, 2025
PubMed
Summary

Targeting Frizzled 6 (FZD6) receptor, highly expressed in advanced prostate cancers, suppresses tumor growth and enhances DNA damage repair. This discovery offers a promising therapeutic strategy for prostate cancer treatment.

More Related Videos

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells
12:13

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells

Published on: August 23, 2014

11.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Related Experiment Videos

Last Updated: Jan 10, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.8K
Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells
12:13

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells

Published on: August 23, 2014

11.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Wnt signaling pathway components, including ligands and frizzled (FZD) receptors, are implicated in prostate cancer progression.
  • Upregulation or mutation of Wnt signaling is common in advanced prostate cancers, promoting proliferation, metastasis, and therapy resistance.
  • Targeting the entire Wnt pathway is challenging due to potential tissue toxicity.

Purpose of the Study:

  • To investigate the role of specific Frizzled receptors in advanced prostate cancer.
  • To evaluate Frizzled 6 (FZD6) as a potential therapeutic target in prostate cancer.
  • To elucidate the mechanisms by which FZD6 influences prostate cancer growth and DNA repair.

Main Methods:

  • Analysis of FZD receptor expression and amplification in advanced prostate cancer tissues.
  • In vitro and in vivo studies involving FZD6 knockdown in prostate cancer cell lines and patient-derived xenograft models.
  • Assessment of DNA double-strand break (DSB) repair, SRC kinase and STAT3 activity, and WEE1/PLK1 signaling following FZD6 knockdown.
  • Kinome-wide CRISPR-Cas9 knockout screen to identify synergistic drug targets with FZD6 inhibition.

Main Results:

  • FZD6 is the most highly expressed and frequently amplified Wnt receptor in advanced human prostate cancers.
  • FZD6 knockdown significantly suppresses prostate cancer cell growth in vitro and in vivo.
  • FZD6 knockdown impairs DNA double-strand break (DSB) repair by downregulating WEE1 via PLK1, linked to reduced SRC kinase and STAT3 activity.
  • FZD6 inhibition enhances prostate cancer cell sensitivity to genotoxic agents and sensitizes cells to PKMYT1 inhibition.

Conclusions:

  • Targeting FZD6, a specific Wnt receptor highly expressed in prostate cancer, offers significant therapeutic potential.
  • FZD6 inhibition disrupts prostate cancer cell proliferation and DNA repair mechanisms.
  • Combining FZD6 inhibition with genotoxic agents or PKMYT1 inhibitors represents a promising therapeutic strategy for advanced prostate cancer.